Patents by Inventor Karine Villeneuve

Karine Villeneuve has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230312557
    Abstract: Provided herein are P2X3 modulators and methods of utilizing P2X3 modulators in the treatment of diseases, disorders, or conditions. Also described herein are pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: February 12, 2021
    Publication date: October 5, 2023
    Inventors: Nathalie CHAURET, Karine VILLENEUVE, Jeremy GREEN
  • Publication number: 20230101612
    Abstract: Described herein are two processes for the preparation of methyl (5)-2-((2-(2,6-difLuoro-4-(methylcarbamol)phenyl)-7-methylimidaz[l,2-a]pyridine-3-yl)methyl)morpholine-4-carboxylate, a P2X3 antagonist, in a stepwise manner and chemical intermediates used in the synthetic processes.
    Type: Application
    Filed: February 12, 2021
    Publication date: March 30, 2023
    Inventors: Nathalie CHAURET, Jeremy GREEN, David R. KRONENTHAL, Karine VILLENEUVE
  • Patent number: 9023864
    Abstract: Compound of formula I are antagonists of the PGD2 receptor, CRTH2, and as such are useful in the treatment and/or prevention of CRTH2-mediated diseases such as asthma.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: May 5, 2015
    Assignees: Merck Sharp & Dohme Corp., Merck Canada Inc.
    Inventors: Carl Berthelette, Michael Boyd, John Colucci, Karine Villeneuve, Joey L. Methot
  • Publication number: 20130244929
    Abstract: The present invention provides novel lipoglycopeptide compounds which are Type 1 signal peptidase inhibitors (SpsB). Compounds of the present invention are useful for the treatment of various bacterial related infectious diseases, particularly when used as a potentiator of a ?-lactam antibiotic such as imipenem and ertapenem. Accordingly, the present invention provides a method for the treatment of bacterial related infections using the compounds described herein, either alone or in combination with a ?-lactam antibiotic.
    Type: Application
    Filed: March 4, 2011
    Publication date: September 19, 2013
    Inventors: Michel Gallant, Karine Villeneuve, Patrick Beaulieu, Joel Robichaud, Helene Juteau, Yves Gareau, Sherman T. Waddell, Nancy Kevin, Xin Gu, Joann Huber, Michael J. Salvatore, JR., Kenneth Wilson, Scott K. Smith, Deborah Zink
  • Publication number: 20130150398
    Abstract: Compound of formula I are antagonists of the PGD2 receptor, CRTH2, and as such are useful in the treatment and/or prevention of CRTH2-mediated diseases such as asthma.
    Type: Application
    Filed: February 7, 2013
    Publication date: June 13, 2013
    Inventors: Carl Berthelette, Michael Boyd, John Colucci, Karine Villeneuve, Joey L. Methot
  • Patent number: 8394819
    Abstract: Compound of formula I are antagonists of the PGD2 receptor, CRTH2, and as such are useful in the treatment and/or prevention of CRTH2-mediated diseases such as asthma.
    Type: Grant
    Filed: February 19, 2010
    Date of Patent: March 12, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Carl Berthelette, Michael Boyd, John Colucci, Karine Villeneuve, Joey Methot
  • Publication number: 20100234415
    Abstract: Compound of formula I are antagonists of the PGD2 receptor, CRTH2, and as such are useful in the treatment and/or prevention of CRTH2-mediated diseases such as asthma.
    Type: Application
    Filed: February 19, 2010
    Publication date: September 16, 2010
    Inventors: Carl Berthelette, Michael Boyd, John Colucci, Karine Villeneuve, Joey Methot